Mark Reed

Assistant Professsor
Krembil Research Institute, 4th Floor, 4KD-474, 60 Leonard Avenue, Toronto, ON, M5S 0S8

Campus

Cross-Appointments

Department of Pharmacology and Toxicology
Department of Chemistry

Fields of Study

Areas of Interest

Medicinal Chemistry and Heterocyclic Chemistry

Biography

Dr. Reed is a medicinal chemist and Scientist at the Krembil Brain Institute, University Health Network (UHN). He is the Director of UHN Therapeutics and Co Chair of UHN’s Collaborative Centre for Drug Discovery, which focuses on identifying and advancing novel therapeutic targets across UHN, academic institutions in Toronto, and international research partners.

Dr. Reed is also a Co Founder and Chief Technology Officer of Treventis Corporation, a Toronto based biotechnology company developing therapies for protein misfolding disorders.

He brings over 20 years of experience in drug discovery spanning both biotechnology and pharmaceutical research environments. Prior to joining UHN, Dr. Reed held senior scientific roles at ICOS Corporation (Seattle) and Schering Plough Research Institute (Cambridge, MA). His work integrates modern medicinal chemistry approaches to discover, optimize, and advance de risked lead compounds toward clinical development, with research spanning central nervous system disorders, anti infectives, immunology, and oncology.

Dr. Reed has published extensively and is an inventor on multiple patents in the areas of synthetic organic chemistry, neurodegeneration, neuropathic pain, inflammation, and fibrosis. He holds cross appointments in the Department of Chemistry and the Department of Pharmacology and Toxicology.